Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant insulin glargine vs Lantus in type 2 diabetes (China)
CTR20170887Phase 3Completed
- Sponsor
- Chongqing Fujin Biopharmaceutical
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Chongqing Fujin Biopharmaceutical. Started Sep 2017; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20170887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170887.